2-Substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines of the formula ##STR1## where n, r1, r2 #4# , r3, r4 and r5 have the meanings given in the description, and their preparation and use.
The novel substances are useful for treating arrhythmia.
|
7. A therapeutic composition having an antiarrhythmic action, comprising: a pharmaceutical excipient and an antiarrhythmically effective amount of the compound of
8. A method of treating cardiac arrhythmias in a patient suffering therefrom, which comprises:
administering an amount of the compound of #4# claim 1 sufficient to exert antiarrhythmic activity in said patient.
|
|||||||||||||||||||||||||||||||
The present invention relates to 2-substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines, processes for their preparation and therapeutic agents containing these compounds and the use of these compounds in the treatment of disorders.
We have found that 2-substituted 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-β-carbolines of the formula I ##STR2## where n is an integer from 2 to 5, R1 is hydrogen, halogen, trifluoromethyl, C1 -C4 -alkyl or C1 -C4 -alkoxy, R2 is hydrogen, or C1 -C3 -alkyl, R3 is C1 -C3 -acyl, R4 is hydrogen or an alkyl or cycloalkyl radical of not more than 4 carbon atoms and R5 is hydrogen or an alkyl or cycloalkyl radical of not more than 4 carbon atoms and, where R4 is hydrogen, may furthermore be C1 -C4 -hydroxyalkyl or C2 -C4 -aminoalkyl in which the amine nitrogen atom can be substituted by C1 -C3 -alkyl or can form part of a 5-membered, 6-membered or 7-membered saturated ring which can contain another nitrogen atom or an oxygen atom as a further heteroatom, and any nitrogen atom present can be substituted by C1 -C3 -alkyl or C2 -C3 -hydroxyalkyl or by phenyl which is unsubstituted or monosubstituted by fluorine, chlorine, methoxy or methyl, or R4 and R5, together with the nitrogen atom, form a 5-membered, 6-membered or 7-membered saturated ring which can be substituted by one or more C1 -C3 -alkyl groups, a hydroxyl group and/or a phenyl group and can additionally contain nitrogen or oxygen as a further heteroatom, and any nitrogen atom present can be substituted by C1 -C3 -alkyl or C1 -C3 -hydroxyalkyl or by phenyl which is unsubstituted or monosubstituted by fluorine, chlorine, methoxy or methyl, and their salts with physiologically tolerated acids possess useful pharmacological properties.
R1 is preferably hydrogen, methyl or chlorine, R2 is preferably hydrogen, methyl or ethyl, R3 is preferably C2 -C3 -acyl, in particular acetyl, and n is preferably 3.
The radical --NR4 R5 is, in particular, dialkylamino or monoalkylamino, dialkylamino being preferred, but may furthermore be one of the following special heterocyclic structures: piperazine, piperidine or morpholine. A particularly suitable cycloalkyl radical is cyclopropyl.
The following compounds are particularly active: 1-[3'-(di-2-methylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydr o-β-carboline, 1-(3'-dipropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-car boline and 1-(3'-isopropyl-propylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.b eta.-carboline.
Further examples include: 1-[3'-diisopropylaminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β- carboline, 1-[3'-(di-2-butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.beta .-carboline, 1-[3'-(t-butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-c arboline, 1-[3'-(isopropyl-2-methylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-te trahydro-β-carboline, 1-[3'-(di-n-butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.beta .-carboline, 1-[3'-(di-2-butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboli ne and 1-[3'-(di-n-butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboli ne.
The novel compounds of the formula I are prepared by a method wherein a compound of the formula II ##STR3## where n, R1, R2 and R3 have the above meanings, is reacted with an amine of the formula
HNR4 R5
where R4 and R5 have the above meanings, and, if required, the resulting compound is converted to its salts with physiologically tolerated acids.
The reaction is advantageously carried out in the presence of one mole equivalent of a tertiary amine, eg. triethylamine, in an inert solvent, such as a saturated cyclic ether, in particular tetrahydrofuran or dioxane, or in a polar aprotic solvent, preferably dimethylformamide, at from 0° to 150°C, and is generally complete in the course of from 3 to 10 hours. The reaction may also be carried out in the presence of an excess of the amino alcohol III employed, the latter serving simultaneously as a solvent and as an acid acceptor.
In the majority of cases, the free compounds of the formula I are obtained in the form of crystals and can be recrystallized from a conventional organic solvent, preferably from a lower alcohol, eg. ethanol, or a lower ester, preferably ethyl acetate, or purified by column chromatography.
If desired, the novel compounds obtained are converted to an addition salt with a physiologically tolerated acid. Examples of conventional physiologically tolerated organic acids are oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid, while examples of conventional physiologically tolerated inorganic acids are hydrochloric acid, hydrobromic acid or phosphoric acid and sulfuric acid. Other suitable acids are mentioned in, for example, J. Pharm. Sci. 66 (1977), 1.
As a rule, the addition salts with acids are obtained in a conventional manner, by mixing the free base or its solution with an appropriate acid or its solution in an organic solvent, for example a lower alcohol, such as methanol, ethanol or propanol, a lower ketone, such as acetone, methyl ethyl ketone or methyl isobutyl ketone, or an ether, such as diethyl ether, tetrahydrofuran or dioxane. To improve the deposition of crystals, it is also possible to use a mixture of the above solvents.
The starting compounds of the formula II are obtained, for example, by reacting a β-carboline derivative of the formula III ##STR4## where n and R1 have the above meanings, with an acylating agent R3 --Cl, where R3 has the above meanings, under trapping conditions in the presence of a base, preferably pyridine, in an inert solvent, preferably dimethylformamide, while cooling, preferably at 0°-15°C
Where R2 in the desired end product is an alkyl radical, this is obtained by reacting the N-2-acyl compound with an alkyl chloride or dimethyl sulfate in an inert solvent.
The compounds III can be prepared by reacting the corresponding tryptamine derivative with an ω-haloaldehyde in a weakly acidic medium at from 50° to 100°C
The novel compounds and their physiologically tolerated addition salts with acids possess useful pharmacological properties. They have a powerful antiarrhythmic action and are therefore particularly useful for the pharmacotherapy of cardiac arrhythmias.
To investigate the antiarrhythmic activity, the substances were administered orally to male Sprague-Dawley rats each weighing 200-250 g. 45 minutes later, the animals were anesthetized with sodium thiobutabarbital (100 mg/kg, administered intraperitoneally). Aconitine was used as the arrhythmogenic substance, and was infused intravenously 60 minutes after administration of the substance (dosage rate: 0.005 mg per kg per min.). In the case of untreated animals (N=52), the ECG showed arrhythmias after 2.74±0.07 min. The onset of these arrhythmias could be delayed by means of antiarrhythmics, the delay achieved being dose-dependent.
Linear relationships exist between the logarithms of the doses (mg/kg) of the test substances and the relative prolongation of the aconitine infusion duration (Δ%), from which relationships the dose which prolongs the infusion duration by 50% can be determined, as the ED 50%.
For further characterization of the substances, the dose at which the first cardiotoxic symptoms (changes in the initial ECG) or neurotoxic symptoms (coordination disturbances, convulsions, etc.) occurred was determined from the decimal-geometric dosage progression (factor .cuberoot.10) used in the experiments. The quotient of the toxic dose and the antiarrhythmically effective dose (ED 50%) is a measure of the therapeutic index of the novel compounds.
The known antiarrhythmic quinidine was used as a comparative substance.
On aconitine-induced arrhythmia, the novel compounds (Table 1) are from 3 (Examples 21 and 4) to 59 times (Example 46) more effective than quinidine. Moreover, they possess a higher therapeutic index than quinidine. The toxic doses are from 12 (Example 42) to 23 times (Example 44) greater than the antiarrhythmically effective doses, whereas the corresponding ratio for quinidine is only 11.
| TABLE 1 |
| ______________________________________ |
| Antiarrhythmic action and toxicity, |
| rat, oral administration |
| Aconitine-induced |
| Substance arrhythmia Toxicity |
| from ED 50% (1) Dose (3) |
| Example No. |
| mg/kg R.A. mg/kg Q (4) |
| ______________________________________ |
| 21 14.6 2.98 215 15 |
| 4 13.5 3.22 215 16 |
| 44 9.21 4.72 215 23 |
| 28 12.4 3.51 215 17 |
| 31 1.71 25.44 21.5 13 |
| 33 1.57 27.71 21.5 14 |
| 42 0.842 51.66 10 12 |
| 43 0.803 54.17 10 13 |
| 46 0.732 59.43 4.64 14 |
| quinidine 43.5 1.00 215 11 |
| ______________________________________ |
| (1) Dose (mg/kg) which prolongs the aconitine infusion duration by 50%. |
| (2) R.A. = relative activity, based on quinidine = 1.00. |
| (3) Dose (mg/kg) after the application of which the first toxic symptoms |
| are observed. |
| ##STR5## |
The present invention therefore furthermore relates to drugs which contain a compound of the formula I or its physiologically tolerated addition salts with acids, and to the use of the novel compounds in the treatment of disorders.
The novel compounds can be used in the conventional solid or liquid pharmaceutical forms, such as tablets, film tablets, capsules, powders, granules, coated tablets, suppositories or solutions. These are prepared in a conventional manner, and to do this the active compounds are mixed with the conventional pharmaceutical assistants, such as tablet binders, fillers, preservatives, tablet disintegrators, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retarding agents and/or antioxidants (cf. H. Sucker et al: Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The forms for administration thus obtained usually contain the active compound in an amount of from 0.1 to 99% by weight.
The dosage of the novel compounds depends on the age, condition and weight of the patient and on the route of administration. As a rule, the daily dose of active compound is from 5 to 75 mg/kg in the case of oral administration and from 1 to 10 mg/kg in the case of parenteral administration.
The examples which follow illustrate the invention.
PAC 1-(3'-Dimethylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carb oline17.1 g (60 millimoles) of 1-(3'-chloropropyl)-1,2,3,4-tetrahydro-β-carboline hydrochloride were dissolved in 240 ml of dimethylformamide while heating, and the solution was then cooled to 5°C in an ice bath. 11.5 g (150 millimoles) of acetyl chloride and immediately thereafter 23.7 g (300 millimoles) of pyridine were added dropwise to the thoroughly stirred solution, the temperature not rising above 5°C during this operation. Thereafter, stirring was continued for a further 2 hours at this temperature, after which the reaction mixture was poured onto ice water. The precipitate was filtered off under suction and washed thoroughly with water. 16.9 g (97%) of crystals of melting point 166°-168° C. (ethanol) were isolated.
16.8 g (55 millimoles) of 1-(3'-chloropropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline were dissolved in 100 ml of dimethylformamide, and 7.03 g (55 millimoles) of dimethyl sulfate were added. Thereafter, a mixture of 15 ml of dimethylformamide and 10.4 g (55 millimoles) of 30% strength sodium methylate solution was added dropwise, while cooling in an ice bath. Stirring was continued for a further 1-2 hours at 5°C, after which the mixture was poured onto 3 liters of stirred ice water. The precipitate was filtered off under suction and dissolved immediately in methylene chloride, and the solution was dried and evaporated down. The residue was purified by column chromatography (silica gel, 95:5 methylene chloride/methanol) or by recrystallization from ethanol with the addition of active carbon. 12.6 g (75%) of product of melting point 93°-95°C were obtained.
5.5 g (18 millimoles) of 1-(3'-chloropropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carboline were suspended in 150 ml of a 40% strength dimethylamine solution in water, and the suspension was transferred to a stirred autoclave, where it was stirred for 5 hours at 150°C under autogenous pressure. Thereafter, the mixture was evaporated to dryness under reduced pressure, the pale oil was dissolved in methylene chloride, water was added, and the aqueous phase was brought to pH 10 with dilute sodium hydroxide solution and then extracted twice with methylene chloride. Drying and evaporating down the organic phase gave 5.8 g of crude product, which was purified by column chromatography (silica gel, mobile phase 95:5 methylene chloride/methanol) or by recrystallization from ethanol with the use of active carbon. 4.7 g (83%) of an oil was isolated. This was converted to the hydrochloride by dissolving it in ether, filtering the solution and adding a solution of HCl in ether. M.p. (hydrochloride)=108°-110°C
The following compounds were prepared by a method similar to that described in Example 1:
2. 1-(3'-Methylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carbo line, m.p.=63°-65°C
3. 1-(3'-Diethylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline∅5 H2 O, m.p.=49°-50°C
4. 1-(3'-Dimethylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline∅ 5H2 O, m.p.=148°-150°C
5. 1-(3'-Methylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline∅5H 2 O, m.p.=75°-77°C
6. 1-(3'-Aminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline, m.p.=90°-92°C
7. 2-(3'-Dimethylaminopropyl)-2-acetyl-6-chloro-1,2,3,4-tetrahydro-β-car boline.H2 O, m.p.=65°-67°C
8. 1-(3'-Methylaminopropyl)-2-acetyl-6-chloro-1,2,3,4-tetrahydro-β-carbo line.H2 O, m.p.=86°-88°C
9. 1-(3'-Dimethylaminopropyl)-2-acetyl-9-ethyl-1,2,3,4-tetrahydro-β-carb oline.H2 O, m.p.=78°-80°C
10. 1-(4'-Dimethylaminobutyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.H.s ub.2 O, m.p.=83°-85°C
11. 1-(3'-Dimethylaminopropyl)-2-acetyl-6-chloro-9-methyl-1,2,3,4-tetrahydro-. beta.-carboline, m.p.=49°-50°C
12. 1-(4'-Dimethylaminobutyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carb oline.1.5H2 O, m.p.=44°-45°C
The following compounds were prepared by a method similar to that described in Example 1b, but with the reaction temperature increased to 155°-180°C and the reaction time to 6-12 hours and using the appropriate pure amine:
13. 1-(3'-Diisopropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β- carboline∅5HCl, m.p.=56°-58°C
14. 1-(3'-Diisopropylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline ∅5H2 O, m.p.=161°-162°C
15. 1-[3'-(2-Butyl)-isopropylaminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro -β-carboline.HCl.2H2 O, m.p.=98°-99°C
16. 1-(4'-Diisopropylaminobutyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline. 0.5 H2 O, m.p.=58°-59°C
17. 1-(3'-Diisopropylaminopropyl)-2-acetyl-6-chloro-9-methyl-1,2,3,4-tetrahydr o-β-carboline, m.p.=50°-52°C
18. 1-[3'-(Di-2-butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.beta .-carboline, oil.
19. 1-[3'-(t.-Butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β- carboline, oil.
20. 1-[3'-(t.-Butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboline , m.p.=69°-71°C
PAC 1-[3'-(4-Methylpiperazin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahydro-β-c arboline.H2 O10.0 g (100 millimoles) of N-methylpiperazine were added to 6.5 g (22 millimoles) of 1-(3'-chloropropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline, and the mixture was stirred for 2 hours at 80°C After cooling, the excess amine was distilled off under reduced pressure, the mixture was taken up in ice water, the solution was extracted with methylene chloride and the organic phase was washed thoroughly with H2 O, dried and evaporated down. The crude product was then purified by column chromatography (silica gel, mobile phase 95:5 mixture of methylene chloride and methanol) or by recrystallization from ethanol with the addition of active carbon. 6.1 g (74%) of product of melting point 165°-167°C were isolated.
The following compounds were prepared by a procedure similar to that described in Example 21:
22. 1-[3'-(2-Piperidin-1-yl)-ethylaminopropyl]-2-acetyl-1,2,3,4-tetrahydro-.be ta.-carboline.H2 O, oil.
23. 1-[3'-(2-Morpholin-1-yl)-ethylaminopropyl]-2-acetyl-1,2,3,4-tetrahydro-.be ta.-carboline.H2 O, oil.
24. 1-[3'-(4-Methylpiperazin-1-yl)-propyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydr o-β-carboline, oil.
25. 1-[4'-(4-Methylpiperazin-1-yl)-butyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro -β-carboline.H2 O, oil.
26. 1-[4'-(4-Methylpiperazin-1-yl)-butyl]-2-acetyl-1,2,3,4-tetrahydro-β-c arboline∅5H2 O, m.p.=76°-77°C
The following compounds were prepared by a method similar to that described in Example 21, but with the reaction temperature increased to 120°-180°C and the reaction time to 3-24 hours:
27. 1-(3'-Isopropylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.H 2 O, m.p.=100°-102°C
28. 1-(3'-n-Butylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline∅5 H2 O, oil.
29. 1-[3'-(2-Butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboline. 0.5H2 O, oil.
30. 1-[3'-(2-Methylpropyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-car boline∅5H2 O, oil.
31. 1-[3'-(Di-n-butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboli ne∅5H2 O, m.p.=81°-83°C
32. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β- carboline, m.p.=138°-140°C
33. 1-[3'-(Di-2-butyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboli ne∅5HCl, m.p.=139°-141°C
34. 1-(3'-Propylaminopropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.H.su b.2 O, oil.
35. 1-[3'-(Dipropyl)-aminopropyl]-2-acetyl-1,2,3,4-tetrahydro-β-carboline , m.p.=106°-108°C
36. 2-(3'-Propylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carbo line.H2 O, oil.
37. 1-(3'-Isopropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-ca rboline.H2 O, oil.
38. 1-(3'-n-Butylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carb oline.HCl.H2 O, m.p.=79°-81°C
39. 1-[3'-(2-Butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-c arboline, oil.
40. 1-(3'-Diethylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carb oline∅5H2 O, oil.
41. 1-[3'-(Di-n-butyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.beta .-carboline, oil.
42. 1-(3'-Dipropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-car boline.HCl.1.5H2 O, m.p.=87°-89°C
43. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydr o-β-carboline, m.p.=137°-139°C; m.p. (hydrochloride.H2 O)=87°-89°C
44. 1-[3'-(4-Methylpiperazin-1-yl)-propyl]-2-acetyl-9-ethyl-1,2,3,4-tetrahydro -β-carboline∅5H2 O, m.p.=58°-61°C
45. 1-(3'-Methylisopropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.be ta.-carboline.HCl.2H2 O, m.p.=81°-83°C
46. 1-[3'-(Isopropylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro- β-carboline.HCl.2H2 O, m.p.=91°-93°C
47. 1-[3'-(n-Butyl)-isopropylaminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro -β-carboline.HCl.H2 O, m.p.=106°-108°C
48. 1-[3'-(2-Methylpropyl)-isopropylaminopropyl]-2-acetyl-9-methyl-1,2,3,4-tet rahydro-β-carboline.HCl.H2 O, m.p.=128°-130°C
49. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-acetyl-6,9-dimethyl-1,2,3,4-tetra hydro-β-carboline, m.p.=108°-110°C
50. 1-(3'-Dipropylaminopropyl)-2-acetyl-6,9-dimethyl-1,2,3,4-tetrahydro-β -carboline, oil.
51. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-acetyl-6-chloro-9-methyl-1,2,3,4- tetrahydro-β-carboline, oil.
52. 1-(3'-Dipropylaminopropyl)-2-acetyl-6-chloro-9-methyl-1,2,3,4-tetrahydro-. beta.-carboline, oil.
53. 1-(4'-Dipropylaminobutyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-β-carb oline.H2 O, oil.
54. 1-[4'-(Di-2-methylpropyl)-aminobutyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro -β-carboline∅5H2 O, m.p.=86°-88°C
55. 1-(4'-Dipropylaminobutyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline∅5 H2 O, oil.
56. 1-[4'-(Di-2-methylpropyl)-aminobutyl]-2-acetyl-1,2,3,4-tetrahydro-β-c arboline∅5H2 O, m.p.=126°-128°C
57. 1-[3'-(2,6-Dimethylpiperidin-1-yl)-propyl]-2-acetyl-9-methyl-1,2,3,4-tetra hydro-β-carboline∅5H2 O, m.p.=153°-155°C
PAC 1-[3'-(4-Methylpiperazin-1-yl)-propyl]-2-acetyl-6-chloro-1,2,3,4-tetrahydro -β-carboline∅5HCl1.6 g (16 millimoles) of N-methylpiperazine and then 1.7 g (16 millimoles) of triethylamine were added to 5.0 g (16 millimoles) of 1-(3'-chloropropyl)-2-acetyl-6-chloro-1,2,3,4-tetrahydro-β-carboline in 30 ml of dimethylformamide, and the mixture was stirred for 3 hours at 120°C, cooled and then poured onto ice water. The resulting mixture was extracted several times with methylene chloride, and the organic phase was washed thoroughly with water, dried and evaporated down. The crude product was purified by column chromatography (silica gel, mobile phase 95:5 mixture of methylene chloride and methanol) or by recrystallization from ethanol with the addition of active carbon. 4.1 g (63%) of product were isolated; decomposition temperature=80°C
The following compounds were prepared by a method similar to that described in Example 58:
59. 1-(3'-Piperidin-1-ylpropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.0 .5HCl, m.p.=134°-136°C
60. 1-(3'-Morpholin-1-ylpropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.H 2 O, m.p.=188°-190°C
61. 1-[3'-(4-Phenylpiperazin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahydro-β- carboline.HCl, m.p.=170°-173°C
62. 1-(3'-(4-(2-Methoxyphenyl)-piperazin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrah ydro-β-carboline.H2 O, m.p.=183°-185°C
63. 1-[3'-(3,5-cis-Dimethylmorpholin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahydro -β-carboline∅5H2 O, m.p.=63°-65°C
64. 1-[3'-(4-Methylpiperidin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahydro-β- carboline.HCl, m.p.=84°-87°C
65. 1-[3'-(4-β-Hydroxyethylpiperazin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetra hydro-β-carboline.1.5H2 O, m.p.=62°-65°C
66. 1-[3'-(4-Hydroxypiperidin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahydro-β -carboline.1.5H2 O, m.p.=66°-69°C
67. 1-[3'-(4-Hydroxy-4-phenylpiperidin-1-yl)-propyl]-2-acetyl-1,2,3,4-tetrahyd ro-β-carboline.H2 O, m.p.=106°-108°C
68. 1-[3'-(3-(4-p-Methoxyphenylpiperazin-1-yl)-propyl)-aminopropyl]-2-acetyl-1 ,2,3,4-tetrahydro-β-carboline∅5H2 O, decomposition point=81°C
69. 1-[4'-(4-(2-Methoxyphenyl)-piperazin-1-yl)-butyl]-2-acetyl-1,2,3,4-tetrahy dro-β-carboline∅5H2 O, m.p.=83°-85°C
70. 1-[4'-(4-(2-Methoxyphenyl)-piperazin-1-yl)-butyl]-2-acetyl-9-methyl-1,2,3, 4-tetrahydro-β-carboline∅5H2 O, m.p.=59°-61°C
PAC 1-(3'-Piperazin-1-ylpropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline.1. 5H2 O7.0 g (82 millimoles) of piperazine were dissolved in 70 ml of dimethylformamide at about 50°C, 5.0 g (17 millimoles) of 1-(3'-chloropropyl)-2-acetyl-1,2,3,4-tetrahydro-β-carboline were added dropwise to the thoroughly stirred solution, stirring was continued for 0.5 hour at 60°C and the solvent was then distilled off under reduced pressure. The residue was partitioned between water and methylene chloride, and the organic phase was washed thoroughly with water, dried and evaporated down to give 5.7 g of a solid, which was purified by column chromatography (silica gel, mobile phase 95:5 mixture of methylene chloride and methanol). 2.6 g (40%) of a product of melting point 65°-67°C were obtained.
The following compounds were prepared by methods similar to those described in Examples 1, 21 and 58:
72. 1-(3'-Dipropylaminopropyl)-2-propionyl-9-methyl-1,2,3,4-tetrahydro-β- carboline, m.p. 72°-74°C
73. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-propionyl-9-methyl-1,2,3,4-tetrah ydro-β-carboline, m.p. 110°-112°C
74. 1-(3'-Dipropylaminopropyl)-2-propionyl-1,2,3,4-tetrahydro-β-carboline , oil.
75. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-propionyl-1,2,3,4-tetrahydro-.bet a.-carboline, m.p. 135°-137°C
76. 1-[3'-(n-Butyl-2-methylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetr ahydro-β-carboline, m.p. 102°-104°C
77. 1-[3'-(n-Butylisopropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahydro -β-carboline, oil.
78. 1-[3-(2-Methylpropylpropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahy dro-β-carboline, m.p. 100°-101°C
79. 1-[3'-(2-Methylpropylethyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrahy dro-β-carboline, m.p. 64°-65°C
The following compounds can be prepared by methods similar to those described in Examples 1, 21 and 58:
80. 1-[3'-(Di-n-butyl)-aminopropyl]-2-propionyl-9-methyl-1,2,3,4-tetrahydro-.b eta.-carboline.
81. 1-[3'-(Di-2-butyl)-aminopropyl]-2-propionyl-1,2,3,4-tetrahydro-β-carb oline.
82. 1-[3'-(Di-n-butyl)-aminopropyl]-2-propionyl-1,2,3,4-tetrahydro-β-carb oline.
83. 1-(3'-Dipropylaminopropyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydro-β-ca rboline.
84. 1-[3'-(Di-2-methylpropyl)-aminopropyl]-2-acetyl-6-methoxy-1,2,3,4-tetrahyd ro-β-carboline.
85. 1-[3'-(Isopropylcyclopropyl)-aminopropyl]-2-acetyl-9-methyl-1,2,3,4-tetrah ydro-β-carboline.
86. 1-(3'-Dicyclopropylaminopropyl)-2-acetyl-9-methyl-1,2,3,4-tetrahydro-.beta .-carboline.
Tablets having the following composition are produced on a tablet press in a conventional manner:
100 mg of the active compound of Example 43
150 mg of lactose
30 mg of corn starch
36 mg of cellulose
10 mg of polyvinylpyrrolidone and
4 mg of magnesium stearate.
Steiner, Gerd, Lenke, Dieter, Mueller, Claus D.
| Patent | Priority | Assignee | Title |
| 4663456, | Sep 16 1985 | American Home Products Corporation | 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders |
| 4766124, | Feb 26 1987 | Wyeth | Beta-carbolin H1-receptor antagonists |
| 4837325, | Feb 26 1987 | Wyeth | Beta-carboline H1 -receptor antagonists |
| 4895853, | Dec 18 1986 | Harbor Branch Oceanographic Institution, Inc. | Antitumor alkaloids |
| 7799931, | Nov 11 2002 | PARK THERAPEUTICS, INC | Spirocyclic cyclohexane compounds |
| 7951948, | Nov 11 2002 | PARK THERAPEUTICS, INC | Spirocyclic cyclohexane compounds |
| 8053576, | Nov 11 2002 | PARK THERAPEUTICS, INC | Compositions containing spirocyclic cyclohexane compounds |
| 8288406, | Mar 27 2008 | Gruenenthal GmbH | Hydroxymethylcyclohexylamines |
| 8288430, | Mar 27 2008 | Grunenthal GmbH | Spiro(5.5)undecane derivatives |
| 8293758, | Mar 27 2008 | Grunenthal GmbH | Substituted spirocyclic cyclohexane derivatives |
| 8357705, | Mar 27 2008 | Grunenthal GmbH | Substituted cyclohexyldiamines |
| 8404740, | Feb 22 2007 | Gruenenthal GmbH | Spirocyclic cyclohexane compounds |
| 8835689, | Mar 27 2008 | Grünenthal GmbH | Substituted 4-aminocyclohexane derivatives |
| 9120797, | Nov 11 2002 | PARK THERAPEUTICS, INC | Process for preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds |
| 9403767, | Mar 27 2008 | Gruenenthal GmbH | Substituted 4-aminocyclohexane derivatives |
| 9580386, | Mar 27 2008 | GRÜNENTHAL GMBH | Substituted 4-aminocyclohexane derivatives |
| 9862719, | Nov 11 2002 | PARK THERAPEUTICS, INC | Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds |
| Patent | Priority | Assignee | Title |
| 2759000, | |||
| 4272539, | Apr 26 1979 | Synthelabo | Pyridoindole derivatives |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jul 20 1983 | STEINER, GERD | BASF Aktiengesellschaft | ASSIGNMENT OF ASSIGNORS INTEREST | 004487 | /0410 | |
| Jul 20 1983 | MUELLER, CLAUS D | BASF Aktiengesellschaft | ASSIGNMENT OF ASSIGNORS INTEREST | 004487 | /0410 | |
| Jul 20 1983 | LENKE, DIETER | BASF Aktiengesellschaft | ASSIGNMENT OF ASSIGNORS INTEREST | 004487 | /0410 | |
| Aug 05 1983 | BASF Aktiengesellschaft | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Apr 18 1986 | ASPN: Payor Number Assigned. |
| Sep 05 1989 | M173: Payment of Maintenance Fee, 4th Year, PL 97-247. |
| Aug 09 1993 | M184: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Aug 25 1997 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| Mar 11 1989 | 4 years fee payment window open |
| Sep 11 1989 | 6 months grace period start (w surcharge) |
| Mar 11 1990 | patent expiry (for year 4) |
| Mar 11 1992 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Mar 11 1993 | 8 years fee payment window open |
| Sep 11 1993 | 6 months grace period start (w surcharge) |
| Mar 11 1994 | patent expiry (for year 8) |
| Mar 11 1996 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Mar 11 1997 | 12 years fee payment window open |
| Sep 11 1997 | 6 months grace period start (w surcharge) |
| Mar 11 1998 | patent expiry (for year 12) |
| Mar 11 2000 | 2 years to revive unintentionally abandoned end. (for year 12) |